In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Rhythm Pharmaceuticals, Inc.

http://www.rhythmtx.com

Latest From Rhythm Pharmaceuticals, Inc.

Latest EU Filings Include A First For BeiGene

Potential treatments from BeiGene, AstraZeneca, Bayer and Cancer Prevention Pharmaceuticals are under review at the European Medicines Agency.

Drug Review Europe

Stacked User Fee Calendar Puts Another Record-Setting Year For US FDA Novel Approvals Within Reach

With goal dates for almost 40 novel drugs and biologics coming up in the second half of 2020 after a record number of first half approvals, even the pandemic looks unlikely to prevent another solid year for innovative drugs at US FDA.

Drug Review Review Pathway

Speedy EU Review For AZ/DS's Enhertu; Cheer Too For BMS/bluebird, Celgene And Rhythm

The European Medicines Agency has agreed to fast track the review of four marketing applications in recent months.The products include AstraZeneca's advanced breast cancer treatment, Enhertu, two investigational CAR-T therapies, and a potential treatment for rare genetic disorders of obesity.

Europe Drug Review

EU Accelerated Assessment Tracker

Alnylam and Eiger join the select group of companies whose products have been granted fast-track status at the European Medicines Agency

Review Pathway Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Rhythm Metabolic, Inc.
UsernamePublicRestriction

Register